KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
Drug Topics articles
- Evaluating Severe COVID-19 Incidence After Initial, Booster Vaccination September 29, 2022Data from periods of Delta and Omicron variant predominance were evaluated in a retrospective cohort study.
- Lecanemab Hopes to Succeed Where Aduhelm Failed September 29, 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
- Improved Glycemic Control, Time in Target Range Found with iLet Bionic Pancreas September 29, 2022The iLet Bionic Pancreas was associated with improved glycemic control and time in target glucose range compared to standard care in a cohort of people with type 1 diabetes aged 6-79 years of age.
- September Month in Review: Top Stories on Drug Topics® September 29, 2022Take a look back at our most popular news from September 2022.
- Increased Menstrual Cycle Length Tied to COVID-19 Vaccine September 28, 2022In a recent study, participants who had received a COVID-19 vaccine saw an average increase in menstrual cycle length of less than 1 day.
- Efficacy and Safety of Ranibizumab and Lucentis for Wet AMD Compared September 28, 2022The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
- The Effects of Psychedelics in Healthy Participants September 28, 2022In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.
- Extend Care and Expand Revenue at the Total Pharmacy Solutions Summit September 28, 2022Tune in on Saturday, October 22, 2022.
- Adjustments in Drug Coverage Criteria in Health Plans Based on New Evidence September 27, 2022However, researchers found that only a small percentage of plans use available real-world evidence studies and economic evaluations in their coverage policies.
- Other JAK Inhibitor Options for Treating Vitiligo September 27, 2022A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.
Pharmacy Times articles
- Omidubicel Shows Clinical Benefit at 3 Years for Individuals With Hematologic Malignancies September 29, 2022The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.
- Tertiary Lymphoid Structure May Improve Immunity for Patients With Ovarian Cancer September 29, 2022A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.
- Addition of Anti-TIM-3 Monoclonal Antibody Could Enhance Effects of Paclitaxel, Docetaxel September 29, 2022Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.
- Drug Therapy Combinations Could Reduce Hospitalization Among Heart Failure Patients with Higher Ejection Fraction September 29, 2022The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection fraction, a subgroup that struggles with insufficient data on treatments.
- FDA Approves Dupilumab for Adult Patients With Prurigo Nodularis September 29, 2022Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.
- Pharmacists Are Empowered Yet Again September 29, 2022FDA revises emergency use authorization to grant prescribing authority for Pfizer’s Paxlovid antiviral treatment for COVID-19.
- NCI Acting Director: Equitable Precision Medicine Requires Concerted Implementation Efforts September 29, 2022Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.
- Pharmacy Focus: Public Health Matters- Properly Treating Youth, Sexual and Gender Minority Populations September 29, 2022Confidential care is a topic that is not discussed as frequently in healthcare, although it is extremely important for adolescents and different vulnerable communities.
- Study: New Mobile Intervention Application May Reduce HIV Risk Among Same-Sex Attracted Young Males September 29, 2022Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.
- FDA Approves Chloroprocaine Hydrochloride Ophthalmic Gel for Ocular Surface Anesthesia September 29, 2022Iheezo is a sterile, single use ophthalmic gel preparation.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com